Table of Contents: 1 Executive Summary 1.1 Market Attractiveness Analysis 1.1.1 Global Atorvastatin API Market, By Application 1.1.2 Global Atorvastatin API Market, By Region 2 Market Introduction 2.1 Definition 2.2 Scope of the Study 2.3 Market Structure 3 Research Methodology 3.1 Research Process 3.2 Primary Research 3.3 Secondary Research 3.4 Market Size Estimation 3.5 Forecast Model 3.6 List of Assumptions 4 Market Dynamics 4.1 Introduction 4.2 Drivers 4.2.1 High Adoption of Atorvastatin in the Treatment of Cardiovascular Diseases 4.2.2 Drivers Impact Analysis 4.3 Restraints 4.3.1 Adverse Health Effects Associated with Atorvastatin 4.3.2 Restraints Impact Analysis 4.4 Opportunities 4.4.1 Growing Prevalence of Dyslipidemia in China 5 Market Factor Analysis 5.1 Value Chain Analysis 5.1.1 Research and Development 5.1.2 Manufacturing 5.1.3 Distribution & Sale 5.1.4 Post-Sale Monitoring   5.2 Porter’s Five Forces Model 5.2.1 Threat of New Entrants 5.2.2 Intensity of Rivalry 5.2.3 Threat of Substitutes 5.2.4 Bargaining Power of Suppliers 5.2.5 Bargaining Power of Buyers 5.3 Regulatory Scenario 5.4 Pipeline Analysis 5.4.1 Introduction 5.4.2 Atorvastatin Calcium Tablets, 40 mg 5.4.3 Atorvastatin calcium 10 mg 5.4.4 Atorvastatin 5.5 Pricing Evolution 6 Global Atorvastatin API Market, by Application 6.1 Introduction 6.2 Hypercholesterolemia 6.3 Hypertriglyceridemia 6.4 Dyslipidemia 6.5 Others 7 Global Atorvastatin API Market, by Region 7.1 Introduction 7.2 North America 7.2.1 U.S. 7.2.2 Canada 7.3 Latin America 7.4 Europe 7.4.1 France 7.4.2 UK 7.4.3 Spain 7.4.4 Germany 7.4.5 Italy 7.4.6 Eastern Europe 7.4.7 Rest of Europe   7.5 Asia-Pacific 7.5.1 China 7.5.2 India 7.5.3 Japan 7.5.4 Rest of Asia-Pacific 7.6 The Middle East and Africa 7.6.1 Middle East 7.6.2 Africa 8 Competitive Landscape 8.1 Competitive Landscape 8.1.1 Introduction 9 Company Profiles 9.1 Teva Pharmaceutical Industries Ltd 9.1.1 Company Overview 9.1.2 Financial Overview 9.1.3 Products Offered 9.1.4 Key Developments 9.1.5 SWOT Analysis 9.1.6 Key Strategies 9.2 Jubilant Life Sciences Ltd 9.2.1 Company Overview 9.2.2 Financial Overview 9.2.3 Products Offered 9.2.4 Key Developments 9.2.5 SWOT Analysis 9.2.6 Key Strategies 9.3 Dr. Reddy’s Laboratories Ltd 9.3.1 Company Overview 9.3.2 Financial Overview 9.3.3 Products Offered 9.3.4 Key Developments 9.3.5 SWOT Analysis 9.3.6 Key Strategies   9.4 Sun Pharmaceutical Industries Ltd 9.4.1 Company Overview 9.4.2 Financial Overview 9.4.3 Products Offered 9.4.4 Key Developments 9.4.5 SWOT Analysis 9.4.6 Key Strategies 9.5 Ind-Swift Labs Ltd 9.5.1 Company Overview 9.5.2 Financial Overview 9.5.3 Products Offered 9.5.4 Key Developments 9.5.5 SWOT Analysis 9.5.6 Key Strategies 9.6 Morepen Laboratories Ltd 9.6.1 Company Overview 9.6.2 Financial Overview 9.6.3 Products Offered 9.6.4 Key Developments 9.6.5 SWOT Analysis 9.6.6 Key Strategies 9.7 Zhejiang Hisun Pharmaceutical Co Ltd 9.7.1 Company Overview 9.7.2 Financial Overview 9.7.3 Products Offered 9.7.4 Key Developments 9.7.5 SWOT Analysis 9.7.6 Key Strategies 9.8 Anuh Pharma Ltd 9.8.1 Company Overview 9.8.2 Financial Overview 9.8.3 Products Offered 9.8.4 Key Developments 9.8.5 SWOT Analysis 9.8.6 Key Strategies 9.9 Centrient Pharmaceuticals 9.9.1 Company Overview 9.9.2 Financial Overview 9.9.3 Products Offered 9.9.4 Key Developments 9.9.5 SWOT Analysis 9.9.6 Key Strategies 9.1 Cadila Pharmaceuticals 9.10.1 Company Overview 9.10.2 Financial Overview 9.10.3 Products Offered 9.10.4 Key Developments 9.10.5 SWOT Analysis 9.10.6 Key Strategies 10 Conclusion

List of Tables: TABLE 1 LIST OF ASSUMPTIONS TABLE 2 ATORVASTATIN API MARKET: PIPELINE ANALYSIS TABLE 3 PRICING EVOLUTION (2016–2018), BY REGION (USD PER KG) TABLE 4 GLOBAL ATORVASTATIN API, BY APPLICATION, 2016–2023 (USD THOUSAND) TABLE 5 GLOBAL ATORVASTATIN API MARKET, BY APPLICATION, 2016–2023 (METRIC TONS) TABLE 6 GLOBAL ATORVASTATIN API MARKET FOR HYPERCHOLESTEROLEMIA, BY REGION, 2016–2023 (USD THOUSAND) TABLE 7 GLOBAL ATORVASTATIN API MARKET FOR HYPERCHOLESTEROLEMIA, BY REGION, 2016–2023 (METRIC TONS) TABLE 8 GLOBAL ATORVASTATIN APIMARKET FOR HYPERTRIGLYCERIDEMIA, BY REGION, 2016–2023 (USD THOUSAND) TABLE 9 GLOBAL ATORVASTATIN API MARKET FOR HYPERTRIGLYCERIDEMIA, BY REGION, 2016–2023 (METRIC TONS) TABLE 10 GLOBAL ATORVASTATIN API MARKET FOR DYSLIPIDEMIA, BY REGION, 2016–2023 (USD THOUSAND) TABLE 11 GLOBAL ATORVASTATIN APIMARKET FOR DYSLIPIDEMIA, BY REGION, 2016–2023 (METRIC TONS) TABLE 12 GLOBAL ATORVASTATIN API MARKET FOR OTHERS, BY REGION, 2016–2023 (USD THOUSAND) TABLE 13 GLOBAL ATORVASTATIN API MARKET FOR OTHERS, BY REGION, 2016–2023 (METRIC TONS) TABLE 14 GLOBAL ATORVASTATIN API MARKET, BY REGION, 2016–2023 (USD THOUSAND) TABLE 15 GLOBAL ATORVASTATIN API MARKET, BY REGION, 2016–2023 (METRIC TONS) TABLE 16 GLOBAL ATORVASTATIN API MARKET, BY APPLICATION, 2016–2023 (USD THOUSAND) TABLE 17 GLOBAL ATORVASTATIN API MARKET, BY APPLICATION, 2016–2023 (METRIC TONS) TABLE 18 NORTH AMERICA ATORVASTATIN API MARKET, BY COUNTRY, 2016–2023 (USD THOUSAND) TABLE 19 NORTH AMERICA ATORVASTATIN APIMARKET, BY COUNTRY, 2016–2023 (METRIC TONS) TABLE 20 NORTH AMERICA ATORVASTATIN API MARKET, BY APPLICATION, 2016–2023 (USD THOUSAND) TABLE 21 NORTH AMERICA ATORVASTATIN API MARKET, BY APPLICATION, 2016–2023 (METRIC TONS) TABLE 22 U.S. ATORVASTATIN API MARKET, BY APPLICATION, 2016–2023 (USD THOUSAND) TABLE 23 U.S. ATORVASTATIN APIMARKET, BY APPLICATION, 2016–2023 (METRIC TONS) TABLE 24 CANADA ATORVASTATIN APIMARKET, BY APPLICATION, 2016–2023 (USD THOUSAND) TABLE 25 CANADA ATORVASTATIN APIMARKET, BY APPLICATION, 2016–2023 (METRIC TONS) TABLE 26 LATIN AMERICA ATORVASTATIN API MARKET, BY APPLICATION, 2016–2023 (USD THOUSAND) TABLE 27 LATIN AMERICA ATORVASTATIN API MARKET, BY APPLICATION, 2016–2023 (METRIC TONS) TABLE 28 EUROPE ATORVASTATIN API MARKET, BY COUNTRY, 2016–2023 (USD THOUSAND) TABLE 29 EUROPE ATORVASTATIN API MARKET, BY COUNTRY, 2016–2023 (METRIC TONS) TABLE 30 EUROPE ATORVASTATIN API MARKET, BY APPLICATION, 2016–2023 (USD THOUSAND) TABLE 31 EUROPE ATORVASTATIN API MARKET, BY APPLICATION, 2016–2023 (METRIC TONS) TABLE 32 FRANCE ATORVASTATIN API MARKET, BY APPLICATION, 2016–2023 (USD THOUSAND) TABLE 33 FRANCE ATORVASTATIN API MARKET, BY APPLICATION, 2016–2023 (METRIC TONS) TABLE 34 UK ATORVASTATIN APIMARKET, BY APPLICATION, 2016–2023 (USD THOUSAND) TABLE 35 UK ATORVASTATIN APIMARKET, BY APPLICATION, 2016–2023 (METRIC TONS) TABLE 36 SPAIN ATORVASTATIN API MARKET, BY APPLICATION, 2016–2023 (USD THOUSAND) TABLE 37 SPAIN ATORVASTATIN API MARKET, BY APPLICATION, 2016–2023 (METRIC TONS) TABLE 38 GERMANY ATORVASTATIN API MARKET, BY APPLICATION, 2016–2023 (USD THOUSAND) TABLE 39 GERMANY ATORVASTATIN API MARKET, BY APPLICATION, 2016–2023 (METRIC TONS) TABLE 40 ITALY ATORVASTATIN API MARKET, BY APPLICATION, 2016–2023 (USD THOUSAND) TABLE 41 ITALY ATORVASTATIN API MARKET, BY APPLICATION, 2016–2023 (METRIC TONS) TABLE 42 EASTERN EUROPE ATORVASTATIN API MARKET, BY APPLICATION, 2016–2023 (USD THOUSAND) TABLE 43 EASTERN EUROPE ATORVASTATIN API MARKET, BY APPLICATION, 2016–2023 (METRIC TONS) TABLE 44 REST OF EUROPE ATORVASTATIN API MARKET, BY APPLICATION, 2016–2023 (USD THOUSAND) TABLE 45 REST OF EUROPE ATORVASTATIN API MARKET, BY APPLICATION, 2016–2023 (METRIC TONS) TABLE 46 ASIA-PACIFIC ATORVASTATIN API MARKET, BY COUNTRY, 2016–2023 (USD THOUSAND) TABLE 47 ASIA-PACIFIC ATORVASTATIN API MARKET, BY COUNTRY, 2016–2023 (METRIC TONS) TABLE 48 ASIA-PACIFIC ATORVASTATIN API MARKET, BY APPLICATION, 2016–2023 (USD THOUSAND) TABLE 49 ASIA-PACIFIC ATORVASTATIN API MARKET, BY APPLICATION, 2016–2023 (METRIC TONS) TABLE 50 CHINA ATORVASTATIN API MARKET, BY APPLICATION, 2016–2023 (USD THOUSAND) TABLE 51 CHINA ATORVASTATIN APIMARKET, BY APPLICATION, 2016–2023 (METRIC TONS) TABLE 52 INDIA ATORVASTATIN API MARKET, BY APPLICATION, 2016–2023 (USD THOUSAND) TABLE 53 INDIA ATORVASTATIN API MARKET, BY APPLICATION, 2016–2023 (METRIC TONS) TABLE 54 JAPAN ATORVASTATIN API MARKET, BY APPLICATION, 2016–2023 (USD THOUSAND) TABLE 55 JAPAN ATORVASTATIN APIMARKET, BY APPLICATION, 2016–2023 (METRIC TONS) TABLE 56 REST OF ASIA-PACIFIC ATORVASTATIN API MARKET, BY APPLICATION, 2016–2023 (USD THOUSAND) TABLE 57 REST OF ASIA-PACIFIC ATORVASTATIN API MARKET, BY APPLICATION, 2016–2023 (METRIC TONS) TABLE 58 THE MIDDLE EAST AND AFRICA ATORVASTATIN API MARKET, BY REGION, 2016–2023 (USD THOUSAND) TABLE 59 THE MIDDLE EAST AND AFRICA ATORVASTATIN API MARKET, BY REGION, 2016–2023 (METRIC TONS) TABLE 60 THE MIDDLE EAST AND AFRICA ATORVASTATIN API MARKET, BY APPLICATION, 2016–2023 (USD THOUSAND) TABLE 61 THE MIDDLE EAST AND AFRICA ATORVASTATIN APIMARKET, BY APPLICATION, 2016–2023 (METRIC TONS) TABLE 62 MIDDLE EAST ATORVASTATIN API MARKET, BY APPLICATION, 2016–2023 (USD THOUSAND) TABLE 63 MIDDLE EAST ATORVASTATIN API MARKET, BY APPLICATION, 2016–2023 (METRIC TONS) TABLE 64 AFRICA ATORVASTATIN APIMARKET, BY APPLICATION, 2016–2023 (USD THOUSAND) TABLE 65 AFRICA ATORVASTATIN APIMARKET, BY APPLICATION, 2016–2023 (METRIC TONS)List of Figures: FIGURE 1 MARKET SYNOPSIS FIGURE 2 MARKET ATTRACTIVENESS ANALYSIS: GLOBAL ATORVASTATIN API MARKET FIGURE 3 GLOBAL ATORVASTATIN API MARKET ANALYSIS, BY APPLICATION FIGURE 4 GLOBAL ATORVASTATIN API MARKET ANALYSIS BY REGION FIGURE 5 GLOBAL ATORVASTATIN API MARKET: MARKET STRUCTURE FIGURE 6 RESEARCH PROCESS OF MRFR FIGURE 7 TOP-DOWN & BOTTOM-UP APPROACH FIGURE 8 MARKET DYNAMICS OVERVIEW FIGURE 9 DRIVERS IMPACT ANALYSIS FIGURE 10 RESTRAINTS IMPACT ANALYSIS FIGURE 11 SUPPLY CHAIN: GLOBAL ATORVASTATIN API MARKET FIGURE 12 PORTER'S FIVE FORCES ANALYSIS OF THE GLOBAL ATORVASTATIN API MARKET FIGURE 13 GLOBAL ATORVASTATIN API MARKET, BY APPLICATION, 2017 (SHARE %) FIGURE 14 GLOBAL ATORVASTATIN API MARKET, BY APPLICATION, 2016–2023 (USD THOUSAND) FIGURE 15 GLOBAL ATORVASTATIN API MARKET BY REGION, 2016–2023 (USD THOUSAND)

Centrient Pharmaceuticals (The Netherlands), Cadila Pharmaceuticals (India), Sun Pharmaceutical Industries Ltd (India), Ind-Swift Labs Ltd (India), Zhejiang Hisun Pharmaceutical Co Ltd (China), Anuh Pharma Ltd (India), Jubilant Life Sciences Ltd (India), Morepen Laboratories Ltd (India), Dr. Reddy’s Laboratories Ltd (India), Teva Pharmaceutical Industries Ltd (Israel)